Phase 2, randomized, double-blind, parallel-group, four week, efficacy and safety trial of [S,S]-reboxetine (PNU-165442G) and atomoxetine in adults with attention deficit hyperactivity disorder

Trial Profile

Phase 2, randomized, double-blind, parallel-group, four week, efficacy and safety trial of [S,S]-reboxetine (PNU-165442G) and atomoxetine in adults with attention deficit hyperactivity disorder

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2008

At a glance

  • Drugs Atomoxetine; Esreboxetine
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 04 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top